Conversely, Hu et al. reported that ATM mutations remained a significant biomarker for shorter TTFT in both univariable and multivariable analyses in treatment-naive patients with CLL [21]. The gene discussed is ATM; the disease is B-cell chronic lymphocytic leukemia.